Vertex Pharma receives CHMP positive opinion for label expansion of Kaftrio in combination with ivacaftor: London Tuesday, March 4, 2025, 14:00 Hrs [IST] Vertex Pharmaceuticals, a ...

With a strong foundation in CF therapies and an expanding pipeline in pain management and other areas, Vertex demonstrates solid financial health with a robust gross margin of 86.1% and revenue of ...

With a strong foundation in CF therapies and an expanding pipeline in pain management and other areas, Vertex demonstrates solid financial health with a robust gross margin of 86.1% and revenue of ...

Sionna Therapeutics recently secured an initial public offering (IPO) of $191m on the Nasdaq stock exchange, signalling ...

Vertex Pharmaceuticals Incorporated ( NASDAQ: VRTX) TD Cowen 45th Annual Health Care Conference Transcript March 3, 2025 3:10 PM ET David Altshuler - Executive Vice President, Global Research and CSO ...

With a strong foundation in CF therapies and an expanding pipeline in pain management and other areas, Vertex demonstrates solid financial health with a robust gross margin of 86.1% and revenue of $11 ...

Here's why four Motley Fool contributors think chip giants Nvidia ( NVDA -0.26%) and Micron Technologies ( MU -1.05%), travel services company Airbnb ( ABNB -0.83%), biotech behemoth Vertex ...

Vertex Pharmaceuticals (VRTX) stock in focus as company secures EU backing to expand label for its cystic fibrosis therapy ...

There are plenty of great investment alternatives in the healthcare sector. You won't need a boatload of money to get started ...

Vertex’s drugs combine both mechanisms to improve CFTR function at the surface of a cell. Waltham, Massachusetts-based Sionna is developing CF drugs that target NBD1, a domain on the CFTR protein.

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its price target upped by Royal Bank of Canada from $407.00 to $408.00 ...

Learn more about whether Alnylam Pharmaceuticals, Inc. or Vertex Pharmaceuticals Incorporated is a better investment based on ...